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REVIEW ARTICLE
Tumour treating fields therapy for glioblastoma: current
advances and future directions
Ola Rominiyi 1,2, Aurelie Vanderlinden1, Susan Jane Clenton3, Caroline Bridgewater3, Yahia Al-Tamimi 2 and Spencer James Collis 1
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival,
despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an
approach in which alternating electrical fields exert biophysical force on charged and polarisable molecules known as dipoles—to
standard therapy, has been shown to extend survival for patients with newly diagnosed GBM, recurrent GBM and mesothelioma,
leading to the clinical approval of this approach by the FDA. TTFields represent a non-invasive anticancer modality consisting of
low-intensity (1–3 V/cm), intermediate-frequency (100–300 kHz), alternating electric fields delivered via cutaneous transducer arrays
configured to provide optimal tumour-site coverage. Although TTFields were initially demonstrated to inhibit cancer cell
proliferation by interfering with mitotic apparatus, it is becoming increasingly clear that TTFields show a broad mechanism of action
by disrupting a multitude of biological processes, including DNA repair, cell permeability and immunological responses, to elicit
therapeutic effects. This review describes advances in our current understanding of the mechanisms by which TTFields mediate
anticancer effects. Additionally, we summarise the landscape of TTFields clinical trials across various cancers and consider how
emerging preclinical data might inform future clinical applications for TTFields.
British Journal of Cancer (2020) 124:697–709; https://doi.org/10.1038/s41416-020-01136-5
BACKGROUND
Glioblastoma (GBM) is the most common and aggressive type of
primary brain tumour, causing roughly 2500 deaths each year in
the United Kingdom1 and the majority of ~200,000 deaths related
to tumours of the central nervous system worldwide each year.2,3
The current standard of care for patients with GBM consists
of maximal surgical resection followed by radiotherapy and
chemotherapy with temozolomide (TMZ). However, even with
this combination of treatment, the median overall survival (OS) is
around 10–16 months, with fewer than 10% of patients surviving
for 5 years or more from the time of diagnosis,4,5 and this scenario
has improved very little over the past four decades.6 There is,
therefore, a critical need for more effective treatment strategies to
improve outcomes for patients faced with this devastating
diagnosis.
Tumour-treating fields (TTFields) represent an emerging non-
invasive anticancer therapeutic modality that involves the transcu-
taneous delivery of low-intensity (1–3 V/cm), intermediate-frequency
(100–300 kHz), alternating electric fields (the approach is also known
as alternating electric field therapy) that exert biophysical force on
charged and polarisable molecules known as dipoles. The beneficial
effects of TTFields therapy are influenced by treatment duration
(with evidence that application >18 h/day improves survival7),
electrical field intensity (where increased intensity confers greater
reduction in cell proliferation) and electrical field frequency,8 which
varies between cancer types—in the case of glioma cells, TTFields
are clinically delivered at an optimum frequency of 200 kHz.9
The frequency of the alternating field has also been shown to
provide different biological effects. Low-frequency electric fields
(<1 kHz) influence cell membrane polarisation and can alter the
behaviour of excitable tissue, such as action potential firing in
neuronal cells.10 On the other hand, high-frequency fields (>500
kHz) cause charged and/or polar molecules inside cells to vibrate,
creating friction and causing kinetic energy to transfer between
molecules, which can be radiated out as thermal energy, leading
to tissue heating.11 Intermediate-frequency alternating electric
fields (100–500 kHz) do not generate enough thermal energy to
cause significant tissue heating and alternate too quickly to trigger
action potential firing, and were consequently originally thought
to lack any beneficial effects.12 However, Kirson et al. demon-
strated that low-intensity alternating electric fields delivered at
100–300 kHz successfully inhibited cancer cell growth, both
in vitro (using cell lines derived from melanoma, glioma, lung,
prostate and breast cancer) and in vivo, by interfering with
microtubule polymerisation during mitosis.9 These findings led to
the first pilot study (EF-07) in GBM patients launched in 200413
and, eventually, to the development of TTFields as a strategy for
treating cancer (Fig. 1).
It has subsequently emerged that, in addition to its antimitotic
effects, TTFields can influence a spectrum of biological processes,
including autophagy, DNA repair, antitumour immunity and
tumour cell migration, in addition to altering cell membrane,
and potentially blood–brain barrier (BBB) permeability. This review
examines the emergence of TTFields as a therapeutic modality to
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treat GBM and highlights molecular mechanisms that are likely to
contribute to its anticancer efficacy. We also summarise the
current landscape of TTFields clinical trials across various cancer
types and consider how emerging preclinical data might inform
future applications for TTFields in the clinic.
TTFIELDS AS AN EMERGING THERAPEUTIC MODALITY
The EF-14 trial represents a landmark study, as it was the first
trial in a decade to show an increase in OS for patients with
newly diagnosed GBM since the addition of temozolomide
(TMZ) chemotherapy to standard care.14–17 Following randomi-
sation at the end of chemoradiotherapy, the addition of TTFields
to maintenance of TMZ chemotherapy significantly increased
median OS by 4.9 months (20.9 vs 16.0 months with TMZ
alone).16,17 Importantly, the addition of TTFields was not
associated with any significant increase in rates of systemic
adverse events (48% vs 44% with TMZ alone, P= 0.58), and the
continuous usage of TTFields appears to be associated with
maintained or enhanced quality of life.18–20 Data from the EF-14
trial led to the approval of TTFields by the FDA in 2015 for newly
diagnosed GBM.21
TTFields delivery
The most widely used clinical TTFields delivery system, Optune
(Novocure™), consists of four transducer arrays, a field generator
and a power source (shown in Fig. 2). For GBM, the four transducer
arrays are attached in pairs, orthogonally to the patient’s scalp.
The patient’s head must be shaved consistently to allow optimal
contact of the transducer arrays with the scalp, and optimal array
positioning is determined using NovoTAL™ (Novocure Ltd., Haifa,
Israel) simulation software based on the location of the tumour
and the size and shape of the patient’s head.22 Each transducer
array is made up of nine ceramic discs, each with a superficial
hydrogel coating to improve conductivity with the skin. The field
generator delivers alternating electric fields through the transdu-
cer arrays across the brain and to the tumour site.
The main adverse event of TTFields is irritant or allergic contact
dermatitis at the site of transducer array attachment resulting from
prolonged exposure to sweat, hydrogel, adhesive or a combination
of these factors. However, skin complications are usually of low
grade (grade 1–2 adverse events) and can easily be managed by
topical corticosteroids, modification of array positioning and/or
protecting the skin with sterile dressing pads.23
The cost-effectiveness of TTFields
Important financial considerations are associated with incorporat-
ing TTFields therapy into the standard of care for GBM patients.
Presently, Novocure, the sole producer of the therapeutic TTFields
delivery systems, rents Optune to patients for a total monthly cost
of around $21,000 (subject to discounts negotiated by healthcare
providers/payers).24 This cost covers the TTFields delivery system,
and includes transducer arrays, array layout planning, patient/
physician training and 24-h technical support.25 Additional
expenses associated with implementing TTFields might include
additional staff and training,22 and costs associated with mana-
ging treatment-related morbidities.26
There have been three major studies estimating the costs
associated with adding TTFields to the standard-of-care therapy
for GBM, all of which use EF-14 trial data. Bernard-Arnoux et al.27
used interim EF-14 data, while Connock et al.28 and Guzauskas
et al.29 used the trial’s final results. During economical modelling,
the assumptions made by Bernard-Arnoux et al. and Connock
et al. were based on a French National Health Insurance
perspective, while analyses by Guzauskas et al. were based on
the US healthcare perspective. All three studies relied on the full
list price of TTFields therapy and therefore do not incorporate
potential discounts negotiated by healthcare payers.
Bernard-Arnoux et al. estimated 0.34 life years gained (LYG)
from the addition of TTFields to maintenance of TMZ, with an
added cost of €185,476, while Connock et al. estimated 0.604 LYG
with an added cost of €453,848. These two studies then estimated
the incremental cost-effectiveness ratio (ICER, a summary measure
that compares the economic value of a particular intervention
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Fig. 1 Historical timeline of the emergence of TTFields as novel therapy for GBM patients. In 2004, the first paper demonstrating the
anticancer effects of TTFields in vitro and in vivo was published.9 Following these promising preclinical data, a number of clinical trials
investigating the safety and efficacy of TTFields for the treatment of GBM were completed (details described at each relevant date), leading to
the approval in 2011 and 2015 of TTFields for the treatment of recurrent and newly diagnosed GBM, respectively.
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with another expressed as cost per LYG) to be €549,909 and
€510,273, respectively. Both studies analysed survival using
statistical models that were unable to account for changing
(decreasing) hazard rates as patients live longer. This is an
important limitation since epidemiological data suggest that as a
patient survives longer, the ongoing probability of death reduces.
For example, analysis of the US SEER database demonstrated
patients alive 5 years after diagnosis had a 70.4% probability of
surviving to 10 years post diagnosis.30 Therefore, although data
from the EF-14 trial suggest that addition of TTFields may increase
5-year OS from 5% to 13%, the studies by Bernard-Arnoux et al.
and Connock et al. did not fully account for the impact of long-
term survivors beyond the trial period. This resulted in reported
incremental lifetime survival benefits (the LYG) close to the
median OS benefit observed within the trial period. By contrast,
Guzauskas et al. integrated EF-14 data with external GBM
epidemiology data and US life expectancy data to estimate
long-term conditional survival (similar integration of oncology trial
and epidemiological data to model long-term survival has
previously been considered by NICE in its decision to licence
ipilimumab for metastatic melanoma31,32). Consequently, the
Guzauskas model estimates 1.25 LYG from adding TTFields to
TMZ and estimates a corresponding ICER of $150,452.
As such, Japan, Israel and Sweden have included TTFields within
their national reimbursement systems following cost-effectiveness
evaluations, whilst Germany has approved TTFields for national
reimbursement based on a clinical comparative effectiveness
review without respect to costs. As noted above, the method of
estimating future survival beyond the time observed in the trial is
a critical assumption within any model. Healthcare payers that
prefer the extrapolated constant hazard rate models of Bernard-
Arnoux and Connock might not be willing to adopt the therapy.
Adoption by healthcare systems that include considerations of
cost-effectiveness as a major driver of decision-making, such as
the NHS in the United Kingdom or the Australian and Canadian
systems,33,34 is likely to depend on how those systems choose to
model long-term survival.
Clinical availability of TTFields
Although the number of patients receiving TTFields has increased
since this approach was first approved for use in GBM patients
(2909 patients worldwide in 2019 compared with 605 patients in
2015),35,36 it is thought that many more patients with approved
indications could benefit from TTFields treatment (on average,
30% of eligible GBM patients currently receive TTFields in
countries where the therapy is available).29,37 Substantial geo-
graphic variation in TTFields availability exists in the clinical usage
of Optune, with the majority of patients who receive TTFields
residing in the United States (roughly twice as many patients
receive TTFields in the United States compared with the rest of the
world).37 As highlighted above, high treatment costs and
differences in long-term survival modelling represent major
drivers of geographical variation in the usage of TTFields
worldwide. Notably, some reluctance to adopt TTFields within
the neuro-oncology community also exists; this might be fuelled
by a range of factors. Firstly, the high cost of TTFields therapy
(discussed above) may represent a barrier to adoption at an
individual or national level. Secondly, valid concerns have been
raised that patients in the control group of the EF-14 trial did not
receive any placebo treatment,16 such as via a sham TTFields
device. However, requiring patients to wear a sham device (ideally
> 18 h per day) with no potential for benefit would likely present
its own ethical challenges,38 and objective endpoints such as OS
(which demonstrated survival benefit with TTFields in the EF-14
trial) are unlikely to be influenced substantially by the lack of
placebo or blinding. Thirdly, a perceived burden of patients
having to carry and wear the device with high compliance may
contribute to reluctance to adopt or prescribe TTFields; never-
theless, objective data suggest that quality of life in these patients
is not reduced.19,20 Critically, much reluctance to adopt TTFields
may stem from the fact that the mechanisms of action for TTFields
are currently less well-defined relative to more established
therapeutic modalities.39 It can be expected that, as technologies
continue to evolve and as competing products enter the market,
TTFields might become increasingly affordable. Additionally, any
enhancement of the therapeutic efficacy of TTFields might also
improve the ICER and facilitate TTFields uptake by healthcare
systems that currently do not deem the technology to be cost-
effective, including the NHS (NICE40). To improve the efficacy of
TTFields, an improved understanding of the diverse mechanistic
effects of this therapy and how these effects can be exploited to
increase the therapeutic index of TTFields-based regimens is
required.
MOLECULAR MECHANISMS FOR THE ANTICANCER EFFECTS OF
TTFIELDS
Increasing evidence suggests the therapeutic effects of TTFields
may be associated with a diverse range of intracellular mechan-
isms. This is perhaps unsurprising considering the abundance of a
broad range of charged and polarisable molecules within cells
upon which TTFields could exert biophysical forces. Although the
spectrum of effects elicited remains incompletely understood,
emerging data suggest that in addition to the antimitotic
effects of TTFields, a multitude of biological processes, including
DNA repair, autophagy, cell migration, permeability and
immunological responses, are perturbed by TTFields to elicit
anticancer effects. A summary of the reported molecular
Fig. 2 The Optune system. Left: the Optune TTFields delivery system consists of four transducer arrays, a field generator and a power source.
Right: a patient wearing the Optune system. Images taken from Novocure, 2020.36
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mechanisms by which TTFields impacts tumour cell toxicity is
shown in Fig. 3.
Antimitotic effects of TTFields
The principle mechanisms of action through which TTFields
application is thought to mediate its therapeutic effects are
antimitotic. The rapidly dividing nature of cancer cells, relative to
normal tissue, underlies their specific sensitivity to TTFields.
Furthermore, comparison of TTFields susceptibility between
various cancer cell lines demonstrates an inverse correlation
between the typical doubling time of cell lines and TTFields-
induced cell death.41 However, the effects of TTFields are also
dependent on the specific frequency of alternating electric fields
applied;9 therefore, calibration of an optimal frequency to exert
cytotoxic effects on a specific cancer cell type within the
intermediate range (100–300 kHz) is also postulated to facilitate
the cancer-specific effects of TTFields on mitosis. During chromo-
some segregation, chromosomes align at the metaphase plate,
and sister chromatids are separated and pulled to opposite poles
of the cell by the mitotic spindle. The mitotic spindle is formed
from an array of microtubules, comprising tubulin polymers, with
each tubulin subunit possessing a relatively high dipole
moment.42 When TTFields are applied, tubulin dimers align with
the electric field, which interferes with the normal microtubule
polymerisation–depolymerisation process during mitosis. This, in
turn, results in abnormal spindle formation, which can lead to
cellular arrest in mitosis for several hours, eventually leading to
mitotic cell death. In other cases, failure of the spindle assembly
checkpoint (SAC),43,44 a mitotic checkpoint ensuring that all
chromosomes are properly attached to the mitotic spindle before
proceeding through to anaphase to enable correct chromosome
segregation,45 might lead to aberrant metaphase exit, abnormal
chromosome segregation, multinucleation and consequently cell
death.43,46 Interestingly, pharmacological inhibition of the SAC key
regulator monopolar spindle 1 (MPS1) kinase using the inhibitor
IN-3 in combination with TTFields has been demonstrated to
increase nuclear abnormalities, G2/M cell-cycle arrest and
apoptotic cell death relative to either treatment used as a single
therapy in glioblastoma cell lines.47 Furthermore, use of this
combination (TTFields+ IN-3) in cultured GBM cells provided a
durable therapeutic response for 72 h following the cessation of
TTFields, highlighting the potential clinical utility of such
combinatorial strategies to resist tumour regrowth during breaks
in the delivery of TTFields therapy to patients (e.g., breaks in
therapy due to TTFields-associated skin toxicity).47 A Phase 1
clinical trial of the potent MPS1 inhibitor BAY121738948
(NCT02366949) has recently been completed; therefore, future
clinical studies assessing the use of SAC inhibition to enhance the
effectiveness of TTFields would be feasible.
With TTFields, although the electric field is uniform in non-
replicating cells, it is non-uniform in dividing cells because of the























































































































































































































































Fig. 3 Summary of the mechanisms of action of TTFields. Low-intensity, intermediate-frequency, alternating electrical fields exert
biophysical forces on a variety of charged and polarisable molecules to elicit a spectrum of biological effects. A Antimitotic effects: during
metaphase, the electric fields are uniform, causing dipolar molecules, such as tubulin, to align with the field. TTFields therefore interfere with
tubulin polymerisation and depolymerisation during metaphase. At anaphase, TTFields prevent localisation of septin proteins to the mitotic
spindle and inhibit assembly of the septin complex into a ring structure at the cleavage furrow. During cytokinesis, the electric fields are non-
uniform, with the fields converging on the cleavage furrow, where the field intensity is the highest. As a result, strong dielectric force is
applied on polarisable objects, pushing them towards the high-intensity region. Together, these effects result in abnormal chromosome
segregation and/or cell death. B DNA repair. TTFields have been shown to downregulate BRCA and Fanconi anaemia (FA) pathway genes,
which have been associated with increased replication stress and increased double-strand break (DSB) formation. Additionally, homologous
recombination repair (HRR) is impaired by TTFields, resulting in reduced efficiency of DSB repair. C Autophagy. TTFields have been suggested
to prevent the inhibitory effects of the PI3K/Akt/mTORC1 signalling pathway on autophagy, resulting in increased activation of autophagy
with TTFields therapy. Further studies are needed to ascertain whether autophagy is activated as a cell survival or cell death signal in response
to TTFields. D Antitumour immunity. TTFields stimulates macrophages (Mø) to secrete reactive oxygen species (ROS), nitric oxide (NO) and
proinflammatory cytokines such as interleukin (IL)-1β, tumour necrosis factor (TNF)-α and IL-6. Additionally, TTFields promote immunogenic
cell death via dendritic cell (DC) recruitment and maturation (mat), ultimately leading to an increase in the accumulation of CD4+ and CD8+
T cells at the tumour site. The combination of TTFields with anti-PD-1 therapy might enhance PD-L1 expression in infiltrating DCs and
macrophages to further enhance antitumour immunity. E Anti-migratory. TTFields reduce the capacity of cancer cells for migration and
invasion through nuclear factor (NF)-κB-, mitogen-activated protein kinase (MAPK)- and phosphatidylinositol 3-kinase (PI3K)/Akt-dependent
mechanisms. F Cell membrane permeability. TTFields increase cell membrane permeability by increasing the number and size of holes in the
cell membrane, thereby potentially enhancing sensitivity to chemotherapeutic drugs.
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Non-uniform electric fields generate forces that cause dielectro-
phoresis, in which the field intensity is increased at the furrow
during cytokinesis, causing charged and/or dipolar molecules to
accumulate here.13 During cytokinesis, the mitotic septin complex
(comprising septins 2, 6 and 7) is normally recruited to the spindle
midline and cleavage furrow at anaphase, and assembles into a
ring structure, where it positions the cleavage furrow to limit
contraction to the equatorial plane and restricts determinants to
separate cortical domains.49,50 The septin complex is also involved
in cross-linking actin, non-muscle myosin II and RhoA, facilitating
actin-based myosin contraction, which directs cleavage furrow
ingression and provides the contractile forces required to
physically separate the forming daughter cells from each
other.50–52 TTFields therapy has been shown to prevent the
localisation of the mitotic septin complex to the spindle midline
and cleavage furrow at anaphase due to TTFields-induced
dielectrophoresis. Failure to localise the septin complex appro-
priately also leads to abnormal chromosomal segregation,
extended duration in mitosis and morphological changes in the
membrane of cells that are characteristic of post-mitotic apoptotic
cell death, such as cell membrane blebbing and rupture46
(Fig. 3A).
Effects of TTFields on the DNA-damage response
Several studies have reported that TTFields sensitise glioma cell lines
to radiotherapy. Exposure to TTFields prior to radiotherapy was
shown to delay the repair of radiation-induced DNA damage,
enhance mitotic catastrophe and reduce glioma cell line survival.53,54
Additionally, cell survival was decreased in non-small-cell lung
carcinoma (NSCLC) cells treated with TTFields prior to or after
radiotherapy treatment compared with either treatment alone;
however, exposing cells to TTFields before radiotherapy was more
toxic.55 These findings could have implications for the timing of
TTFields application in future preclinical and clinical studies, with
TTFields application prior to, or immediately after, radiotherapy likely
to optimise therapeutic efficacy. TTFields therapy has also been
suggested to interfere with the efficiency of DNA repair. Giladi et al.
found more numerous γH2AX foci (an established marker of DNA
damage) in glioma cells 24 h post radiotherapy in the combination
group compared with either treatment alone. These results suggest
that the increased sensitivity to radiotherapy observed with TTFields
could be mediated through both an increase in DNA damage and
reduced repair capacity following TTFields treatments.53
Consistent with these findings, differential gene expression
analysis revealed that the expression of genes encoding the DNA-
repair proteins BRCA1, ATRIP, MLH1, MRE11A, FANCM and FANCD2,
was significantly downregulated in TTFields-treated NSCLC cell lines
compared with baseline expression, and that this downregulation
was more pronounced in cell lines that were more sensitive to
TTFields relative to cell lines that are more resistant to TTFields.55
BRCA1 plays a central role in homologous recombination DNA repair
(HRR), recruiting, along with BRCA2, RAD51 filaments to sites of DNA
damage.56–58 During homologous recombination, RAD51 mediates
sequence homology search and strand invasion into the sister
chromatid, and prevents nucleolytic degradation of stalled replica-
tion forks.59 RAD51 foci can therefore be used to monitor HRR
efficiency, with cells that retain RAD51 foci for 24 h following
radiotherapy being associated with persistent DNA double-strand
breaks (DSBs) and eventually cell death. Giladi et al. showed an
increase in persistent RAD51 foci 24 h following combination
treatment (radiotherapy plus TTFields) compared with either
treatment alone, suggesting that the reduced repair efficiency seen
with TTFields could be the result of impaired HRR following TTFields
application. Notably, non-homologous end-joining repair kinetics
were not affected by TTFields treatment.53
In addition to their role in HRR, BRCA genes cooperate with
Fanconi anaemia pathway proteins to maintain DNA replication
fork stability.60 Karanam et al. showed that replication stress was
increased with TTFields, and that replication fork dynamics were
impaired.61 Measuring the incorporation of labelled nucleotides
into newly synthesised DNA strands during DNA replication serves
as a robust readout for replication stress and replication fork
dynamics.62 Karanam et al. showed that DNA fibre length was
shorter in H157 and H1299 cells treated with TTFields compared
with DNA fibre length in untreated cells, and the difference in
DNA fibre length between groups increased over time, indicating
that TTFields interfere with replication fork progression and
induce replication stress. In addition, the authors demonstrated
the presence of other replication-stress markers following TTFields
treatments,61 such as increased replication protein A (RPA) foci
(RPA is recruited to single-stranded DNA (ssDNA) intermediates
during DNA replication, where it protects exposed ssDNA from
nucleases and prevents ssDNA from reannealing63) and increased
R-loop formation (regions of 3-stranded nucleic acid that form
when a replication fork collides with the transcription machinery;
these are produced at a higher rate during replication stress).64
Finally, the authors demonstrated reduced expression of the mini-
chromosome maintenance (MCM) complex genes MCM6 and
MCM1061 (the MCM complex functions as a DNA helicase that is
crucial for replication initiation and replication fork assembly).
Collectively, these data suggest that downregulation of BRCA/
Fanconi anaemia pathway genes by TTFields results in an increase
in replication-stress-induced DSBs and reduced DSB-repair effi-
ciency due to impaired HRR kinetics (Fig. 3B). As cancerous cells
often demonstrate overreliance on a reduced repertoire of DNA-
damage response processes,65,66 future combinatorial strategies
that exploit these TTFields-induced vulnerabilities might be
particularly effective.
Effects of TTFields on autophagy
The roles of autophagy in cancer are diverse. During the early
phases of cancer initiation, the upregulation of autophagy exhibits
tumour-suppressive functions, whereas autophagy can be acti-
vated to promote cancer cell survival and treatment resistance
during the later stages of cancer development.67 Previous studies
have demonstrated that TTFields-treated cells display features that
are characteristic of autophagy, such as increased cell volume
and granularity and the formation of double-membraned
autophagosomes.46,68–70 When cells undergo autophagy,
microtubule-associated protein light-chain 3 (LC3-I) is converted
into LC3-II through lipidation by autophagy-related protein 7
(ATG7), enabling its recruitment to the autophagic vesicle
membrane, where it activates ATG5, a key component in
autophagic vesicle formation.71 As such, LC3 is often used as a
marker for monitoring autophagy.72 Shteingauz et al. observed an
increase in the LC3-II protein in cancer cells following the
application of TTFields.68 However, increased levels of LC3-II do
not always correlate with increased autophagy, and can also
signify the reduced turnover of autophagosomes owing to defects
in autophagosome transport and fusion of the autophagosome
with the lysosome.73 Consequently, autophagic flux, which
describes the entire process of autophagy (autophagosome
formation, maturation, fusion with lysosomes and lysosomal
degradation of cytoplasmic constituents) must be measured to
determine the degree of autophagy. Measuring the difference in
LC3-II levels in the presence and absence of a lysosome inhibitor,
such as chloroquine (which inhibits autophagosome–lysosome
fusion), allows the determination of how much LC3-II is degraded
in a lysosome-dependent manner because it stops autophagic flux
before lysosomal degradation can take place, and therefore
indicates the extent of degradation that would have taken place
during the treatment, reflecting the degree of autophagy.74
Combining chloroquine with TTFields was shown to significantly
increase LC3-II levels in cells relative to control and relative to
TTFields-treated cells in the absence of chloroquine, indicating
that TTFields increase autophagic flux and activate autophagy.68
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TTFields therapy has also been shown to induce abnormal
chromosomal segregation,43 and aberrant mitotic events have
been linked to the increased activation of autophagy.75 TTFields-
treated cells that underwent aberrant mitosis (identified as cells
displaying abnormal numbers of chromosomes or abnormal cell
morphology) were shown to be more likely to activate autophagy
in comparison with cells that had not divided over the course of
the experiment or cells that underwent normal cell division,68
suggesting that TTFields-induced aberrant mitotic events could be
driving activation of autophagy. The phenomenon of ‘doryphagy’
describes the specific autophagy-mediated turnover of centroso-
mal satellites that leads to chromosome-segregation errors and
chromosomal instability.76 Given the data described above, it
would be interesting to determine if TTFields impact on
centrosomal proteins through autophagy-mediated degradation.
The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/
mammalian target of rapamycin (TOR) signalling pathway is known
to suppress the activation of autophagy.77 Kim et al. found that the
expression of Akt2 and the downstream targets of mTOR complex
(mTORC)1, 4E-binding protein 1 (4EBP1) and 70-kDa ribosomal
protein S6 kinase (p70S6K), was downregulated in glioma cells upon
TTFields therapy, and that phosphorylation of mTOR at Ser2448 was
reduced. Re-expressing Akt2 prevented the TTFields-mediated
induction of autophagy, indicating that Akt2 pathway signalling
regulates autophagy in TTFields-treated cells, and that TTFields
activate autophagy by suppressing the inhibitory action of PI3K/Akt/
mTOR pathway on autophagy.69 Additionally, the function of
mTORC1 is inhibited by various types of stress within the cell. For
example, AMP-dependent kinase (AMPK), which phosphorylates and
inhibits mTORC1, thereby suppressing the inhibitory effects of
mTORC1 on autophagy,78 is activated by low-energy (ATP) levels.
Shteingauz et al. demonstrated that intracellular levels of ATP were
reduced in surviving cells after TTFields application, and that
knockdown of AMPK prevented TTFields-mediated upregulation of
autophagy, suggesting that activation of AMPK was required for
increased activation of autophagy in TTFields-treated cells.68
Together, these data suggest that activation of autophagy in
TTFields-treated GBM cells might be mediated via regulation of the
PI3K/Akt/mTOR signalling pathway (Fig. 3C).
Whether activation of autophagy by TTFields serves as a cell
survival or a cell death signal is still unclear. Some studies have
shown that inhibition of autophagy enhances the killing of cancer
cells with TTFields, suggesting that upregulation of autophagy
might act as a mechanism of resistance to TTFields, and thus
highlighting the potential use of autophagy inhibition as a
strategy to enhance the therapeutic efficacy.68 Others, however,
have reported that autophagy inhibition reduces the killing of
cancer cells with TTFields.69 For example, Silginer et al. reported
that TTFields-mediated cell death took place in a caspase-
independent manner, and that autophagy played an important
role in TTFields-mediated cell death.70 However, TTFields-
mediated cell death has been shown to occur through both
caspase-dependent (characteristic of apoptotic cell death) and
caspase-independent pathways,43,46,70 suggesting that the type of
cell death activated upon TTFields application might be condi-
tional, influenced, for example, by cancer type and genetic
context.70,79 The regulatory mechanisms that direct autophagy to
act as a pro-survival or pro-death signal following TTFields warrant
further study, but could facilitate the identification of defined
populations of patients that are most likely to benefit from
concomitant inhibition of autophagy.
TTFields and innate immunity
Macrophages play a central role in governing the nature of
immune responses, and represent the dominant infiltrating
immune cell population in GBM, constituting ~30–40% of the
tumour mass.80 Macrophages can assume one of two phenotypes:
M1 macrophages are considered proinflammatory and secrete
proinflammatory cytokines, such as interleukin-1β (IL-1β), IL-12
and tumour necrosis factor-α (TNF-α),81 to initiate an immune
response; M2 macrophages are involved in the resolution of
inflammation and release anti-inflammatory cytokines, including
IL-10 and transforming growth factor-β (TGF-β). In addition,
macrophages are themselves stimulated by cytokines.81,82 Inflam-
matory cytokines stimulate macrophages to produce nitric oxide
(NO), which induces toxic reactions against invading pathogens
and regulates the function of host immune cells, such as T cells,
antigen-presenting cells, mast cells, neutrophils and natural killer
cells. NO is converted from L-arginine by the inducible NO
synthase (iNOS) during inflammation. The proinflammatory
cytokines TNF-α, IL-1β and IL-6 mediate the upregulation of iNOS
in macrophages by activating the nuclear factor κB (NF-κB)
transcription factor and the mitogen-activated protein kinase
(MAPK) protein p38, extracellular signal-regulated kinase (Erk)1/2
and c-Jun-activated kinase (JNK). Additionally, when macrophages
are first activated by cytokines, the low concentrations of NO can
stimulate the NF-κB signalling pathway to upregulate iNOS
expression in a positive-feedback loop.83 Park et al.84 showed
that the mRNA expression levels of IL-1β and TNF-α were
significantly increased in RAW 264.7 murine macrophage cells
following TTFields treatment. TTFields therapy also upregulated
iNOS at both the mRNA and protein levels, consistent with the
increased production of NO in these cells. Additionally, an increase
in IL-1β, TNF-α and IL-6 secreted into the medium of TTFields-
treated RAW 264.7 cells co-cultured with 4T1 cancer cells was
detected. These data indicate that TTFields promote phenotype
skewing of macrophages towards a proinflammatory phenotype.
Furthermore, 4T1 cells that were exposed to the culture medium
from TTFields-treated RAW 264.7 cells displayed a reduction in cell
viability compared with 4T1 cells that were exposed to the culture
medium of untreated RAW 264.7 cells, suggesting that TTFields-
mediated activation of macrophages promotes antitumour
immunity.84
Reactive oxygen species (ROS), which are also produced by
macrophages, function as secondary messengers that activate
both NF-κB and MAPK signalling pathways within these cells.85
Under normal circumstances, the inhibitor of NF-κB (IκB-α) protein
is bound to, and inhibits, NF-κB, sequestering it in the cytoplasm.
Both ROS and TNF-α can mediate the activation of MAPK
signalling85 and IκB kinase (IKK), which phosphorylates IκB-α,
resulting in its polyubiquitination and subsequent proteasomal
degradation. This process releases the p65 transcriptional subunit
from the NF-κB complex, which can then translocate to the
nucleus and regulate the transcription of target genes, including
those encoding proinflammatory cytokines.86 Interestingly, ROS
secretion was increased in RAW 264.7 cells following TTFields
treatment. Additionally, TTFields-treated RAW 264.7 cells displayed
increased phosphorylation of IκB-α, the NF-κB p65 subunit and
p38 MAPK.84 These data suggest that TTFields therapy mediates
its antitumour immunity effects via the regulation of NF-κB and
MAPK signalling pathways in RAW 264.7 macrophages, and raises
the potential that TTFields could provide a way to overcome the
mechanisms of immune escape typically associated with
glioblastoma.87
TTFields enhance immunogenic cell death
Using a rabbit model of metastatic cancer, Kirson et al.88 showed
that applying TTFields therapy to VX-2 cell (squamous cell
carcinomas) implanted within the kidney capsule significantly
reduced distant metastases in the lungs. As the lungs were not
directly treated, the observed abscopal effect was most likely
mediated by the immune system. Indeed, there was a significant
increase in the infiltration of CD45+ T cells, CD4+ T helper cells
and CD8+ cytotoxic T cells to the lungs of the treated rabbits,
confirming that TTFields can stimulate antitumour immunity
in vivo.88
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Voloshin et al.89 showed that TTFields induce the membrane
translocation and subsequent exposure of the chaperone calreticu-
lin, as well as secretion of the damage-associated molecular pattern
ATP and high-mobility group box protein 1 (HMGB1), both of which
lead to immunogenic death in cancer cells. Furthermore, dendritic
cells, when co-cultured with TTFields-treated cells, demonstrated
enhanced phagocytic activity and upregulation of the major
histocompatibility complex (MHC) class II and the activation markers
CD40 and CD80, indicative of enhanced dendritic cell maturation
and immunogenic cell death. Notably, combining TTFields with an
inhibitor of programmed cell death protein 1 (PD-1) reduced the
tumour volume in lung- and colon-tumour-bearing mice compared
with sham control and compared with mice treated with TTFields or
the inhibitor alone,89 suggesting that PD-1 inhibition might further
promote the antitumour immune response elicited by TTFields
treatment. PD-1 normally functions by disrupting T-cell activation,
thereby preventing activation of the immune response; this immune
checkpoint, and others, is essential to prevent hyperactivation of the
immune system, which can result in autoimmune disorders (e.g.,
rheumatoid arthritis and multiple sclerosis), but cancer cells can
exploit this mechanism in order to evade immune-response-
mediated cell death.90 Immune checkpoint inhibitors such as anti-
PD-1 thus enable T cells to kill cancer cells again and further
enhance the anticancer immune response induced by TTFields
therapy (Fig. 3D). Several clinical trials assessing the use of immune
checkpoint inhibitors in glioblastoma are ongoing, whilst the
combination of TTFields with anti-PD-1 therapy is currently being
assessed in patients with NSCLC (NCT02973789),91 potentially
providing an important platform for future clinical studies assessing
a similar combination to treat patients with a glioblastoma.
TTFields suppress cancer cell migration
GBMs are locally invasive tumours. As the extensive migration and
infiltration of glioma cells into healthy brain tissue contribute to
therapeutic resistance and poor outcomes, restraining these
properties represents an appealing therapeutic strategy.92 Studies
by both Kim et al. and Silginer et al. demonstrated that the
application of TTFields therapy to established GBM cells significantly
reduced cancer cell migration and invasion, as determined through
the use of scratch wound-healing and Transwell systems.54,70
Silginer et al. also identified similar anti-migratory effects of TTFields
on glioma-initiating cells, which can undergo self-renewal and
initiate tumorigenesis; this is an important finding given the key
role played by glioma-initiating cells in mediating therapeutic
resistance and recapitulating the tumour cell hierarchy following
treatment.93–95 Interestingly, the results indicated that the anti-
infiltrative effects of TTFields were mediated by downregulation of
the NF-κB, MAPK and PI3K/AKT signalling pathways in glioma cells,
which modulate the transcriptional regulation of matrix metallopro-
teinase (MMP)2 and MMP9 (Fig. 3E).54 Additionally, TTFields were
found to reduce the expression of vascular endothelial growth factor
(VEGF) and hypoxia-inducible factor (HIF)-1α, and to suppress
vascular development using human umbilical vein endothelial cells
within an in vitro Matrigel™-based endothelial tube-formation
assay.54 The ability of glioma-initiating cells to remodel the tumour
microenvironment, including via complex interplay with endothelial
cells, has been implicated in their aggressive nature.95 These
findings therefore suggest that TTFields may restrain the invasive-
ness of GBM by reducing MMP-mediated cleavage through ECM
proteins in the surrounding brain by glioma cells and potentially
reducing nutrient supply by limiting neovascularisation through
reduced VEGF and HIF-1α production in glioma cells.
TTFields enhance cell membrane permeability and intracellular
drug concentrations
Whereas integral membrane proteins mediate the transport of
large molecules across the cell membrane by passive or active
transport, small molecules and ions can simply diffuse across the
cell membrane through small holes that punctuate the surface of
the cell membrane.96 Chang et al.97 used scanning electron
microscopy to reveal that TTFields increased both the number and
the size of holes in the membrane of glioma cells, with an average
hole size of 240.6 ± 91.7 nm2 in TTFields-treated cells compared
with 129.8 ± 31.9 nm2 in untreated cells. Importantly, these
changes appear to be cancer-specific, as no changes in the
membrane structure of healthy human fibroblast cells were
observed. Additionally, the authors observed a significant increase
in the uptake of membrane-associating reagents with a size of 20
kDa, and no larger than 50 kDa, into glioma cells with TTFields.
These changes were reversible and returned to normal within 24 h
of ceasing TTFields treatment97 (Fig. 3F). Emerging data also
suggest that the application of TTFields therapy might interfere
with the integrity of the blood–brain barrier by transiently
disrupting the localisation of tight-junction proteins such as
claudin 5 and ZO-1.98 Additional studies and their results will be
highly informative.
These findings suggest that TTFields therapy has the potential
to increase intracellular/intratumoral concentrations of che-
motherapy, and therefore provides a rational explanation for the
reported increase in sensitivity to chemotherapeutic drugs
observed following TTFields therapy—perhaps even explaining
the significant improvement in patient survival observed in the EF-
14 trial when TTFields was combined with TMZ.16 Therefore, in
theory, TTFields might enhance the clinical efficacy of many
pharmacotherapies, independent of drug mechanism, by increas-
ing the drug concentration selectively within neoplastic cells.
These studies also highlight important implications for the rational
design of TTFields–chemotherapy combinations and drug sche-
duling, since ensuring TTFields delivered prior to drug adminis-
tration could help optimise therapeutic response (e.g., exit may be
beneficial to delay drug doses until a few hours after scheduled
breaks in TTFields therapy).
AN OVERVIEW AND UPDATE ON TTFIELDS CLINICAL TRIALS
The emerging landscape of clinical trials assessing TTFields
therapy to treat intracranial and extracranial tumours has to date
supported FDA approvals (and a European CE mark for Optune)
for the indications of recurrent and newly diagnosed glioblastoma
and mesothelioma (discussed below). Additionally, over 25
registered clinical trials assessing TTFields are currently active.99
Recurrent GBM
From 2006 until 2009, 237 patients with recurrent GBM were
enrolled in a randomised Phase 3 clinical trial (EF-11, the first
Phase 3 trial to investigate the efficacy of TTFields as a
monotherapy in humans) and treated with either TTFields (120
patients) or chemotherapy alone (117 patients). The primary
endpoint was OS, and secondary endpoints included progression-
free survival (PFS), 1-year survival, quality of life (QoL) and safety/
toxicity. Although there was no significant difference in OS or PFS
in TTFields-treated patients compared with the chemotherapy
control group (6.6 vs 6.0 months and 2.2 vs 2.1 months,
respectively), TTFields therapy was concluded to be just as
effective as physician’s choice chemotherapy in treating recurrent
GBM, with the added benefits of fewer severe adverse events and
overall improvement in QoL.20 The results of the EF-11 trial led to
the FDA approval of TTFields as a treatment for GBM recurrence
following standard-of-care chemotherapy.21
Newly diagnosed GBM
Between 2009 and 2014, a randomised, Phase 3 clinical trial (EF-
14) enrolled patients to receive either TTFields plus adjuvant TMZ
(466 patients) or TMZ alone (229 patients). All patients had
completed initial radiotherapy with concomitant TMZ prior to
randomisation. The study primary endpoint was PFS. The
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secondary endpoint was OS, with further exploratory endpoints,
including PFS at 6 months, QoL and cognitive function. TTFields
with TMZ significantly increased both the PFS and OS of newly
diagnosed GBM patients by 2.7 months (6.7 vs 4.0 months, P <
0.001) and 4.9 months (20.9 vs 16.0 months, P= 0.004),
respectively, compared with treatment with TMZ alone. Two years
into the trial, 43% of patients randomised to receive TTFields plus
TMZ treatment were still alive, compared with 29% in the TMZ-
only group. The addition of TTFields to TMZ did not compromise
QoL or increase the rate of serious adverse events.16 Following the
results of the EF-14 trial, the FDA approved TTFields together with
concomitant TMZ for the treatment of newly diagnosed GBM after
maximal resection and completion of standard-of-care radio-
therapy and chemotherapy.21
Brain metastases and extracranial tumours
Clinical trials assessing the impact of TTFields to treat brain
metastases from NSCLC and a range of other extracranial
malignancies (including mesothelioma, NSCLC and pancreatic,
ovarian, hepatic and gastric cancer) are actively progressing. These
trials are summarised in Table 1. Although it is not possible to
provide a detailed commentary on each trial within this review, the
results of the STELLAR trial, completed in 2019, should be
highlighted.100 This single-arm Phase 2 clinical trial examined the
safety and efficacy of continuous TTFields delivery (>18 h per day)
at 150 kHz in combination with standard-of-care chemotherapy to
treat patients with unresectable treatment-naive malignant pleural
mesothelioma. The trial demonstrated encouraging median OS
and PFS of 18.2 and 7.6 months, respectively, which are considered
to represent a major advance compared with OS and PFS of 12.1
and 5.7 months for historical controls receiving standard-of-care
chemotherapy only.101 In light of the STELLAR trial, TTFields
received FDA approval for use in combination with chemotherapy
to treat malignant pleural mesothelioma under humanitarian
device exemption102 (a regulatory framework which helps facilitate
device approval for rare diseases; this recognises the challenge of
generating clinical evidence with a limited patient population, and
whilst stringent safety criteria must be maintained, the device can
be exempt from some effectiveness requirements, subject to
certain profit and use restrictions). This approval established
TTFields therapy as the first FDA-approved mesothelioma treat-
ment in over 15 years. A summary of key completed and ongoing
TTFields clinical trials is detailed in Table 1.
CONCLUSIONS AND FUTURE OPPORTUNITIES
Further potential applications for TTFields include expanding the
population of patients receiving this therapy through additional
trials for which existing and emerging preclinical data support
clinical studies (e.g., colorectal, renal and breast). In addition,
investigation of cancers that have not yet been studied in the
context of TTFields—haematological cancers, for example—could
be considered. Several key ongoing clinical trials (see Table 1)
evaluating the efficacy of combining TTFields with existing antic-
ancer agents in a range of cancer types together with increasing
mechanistic data derived from preclinical studies will help to clarify
the role of TTFields in treatment regimens and establish the
feasibility of making TTFields more readily available across a wider
range of cancer types in the years to come. As cancers from different
anatomical regions gain attention, transducer array redesigns might
be required to ensure optimal TTFields delivery in new anatomical
regions whilst maintaining QoL.
Solid paediatric malignancies, including brain tumours, repre-
sent a clear indication in need of less harmful anticancer
therapies.103 Ongoing preclinical research suggests that TTFields
might demonstrate efficacy in paediatric GBM, medulloblastoma
and ependymoma,104 whilst limited case reports/series suggest
that TTFields treatment in children is likely to be safe.105,106 One of
these studies indicated that TTFields was tolerable in five
paediatric patients with high-grade glioma, aged between 10
and 20, three of whom showed partial responses when they
received TTFields alongside chemotherapy and/or radiation.106
The study of the use of TTFields to improve outcomes and avoid
the substantial morbidity associated with use of chemotherapy
and radiotherapy in children is an area of investigation that should
be prioritised. To this end, an investigator-initiated study
(NCT03033992) testing the feasibility of TTFields for children with
recurrent or progressive supratentorial high-grade glioma and
ependymoma is ongoing; additional studies and long-term follow-
up data would, however, be desirable.
Regarding the treatment of adult patients with newly diagnosed
GBM, even with improvements in outcome following the addition
of TTFields, survival for most patients remains under 2 years,16
highlighting an ongoing need to further enhance the efficacy of
TTFields and current chemoradiotherapy. The EF-14 trial concluded
that compliance with TTFields therapy correlated with improved
OS in GBM patients. Patients with a compliance of over 90% (≥ 18 h
of daily TTFields) had a median OS of 28.7 months from diagnosis
and a 5-year survival rate of 29.3%,7 and simulation-based analysis
of the EF-14 Phase 3 data suggests that the overall dose of TTFields
delivered at the tumour site strongly correlates with OS.107
Considering these findings, it is clear that any method that could
effectively increase TTFields usage time (such as improved
portability of the clinical device108) or increase intensity at target
regions should support improvements in therapeutic efficacy.
Emerging preclinical data outlined in this review suggest a
strong mechanistic rationale for the use of TTFields in combina-
tion with a number of molecularly targeted therapies to improve
efficacy. Preclinical data have shown that PD-1 inhibitors can
increase antitumour immunity with TTFields89 and underpin a
currently ongoing clinical trial investigating the efficacy of
combining PD-1 inhibitors with TTFields for the treatment of
patients with NSCLC (LUNAR NCT02973789—see Table 1). A state
of ‘BRCAness’ (deficiency in BRCA or related HRR function)
following TTFields-mediated downregulation of BRCA genes
(discussed above) has been described.53,55 BRCA-deficient cancers
are characterised by an inherent vulnerability to DNA single-strand
break repair inhibitors, such as PARP inhibitors,109,110 under the
concept of synthetic lethality due to impaired HRR efficiency.111
Preclinical data have shown TTFields and olaparib, a PARP1
inhibitor, synergised to increase cell killing compared with either
treatment alone.61 Future trials combining TTFields with PARP
inhibition, including an active trial (recruitment commenced in
early 2020) using niraparib and TTFields in GBM (NCT04221503),
will be highly informative. The combination of TTFields with other
DNA-damage response processes should also be considered. In
this respect, our team are actively investigating TTFields
combinations that incorporate inhibition of the Fanconi anaemia
pathway, as this pathway has been implicated in therapeutic
resistance to TMZ112–114 and also demonstrates synthetic lethality
with loss of BRCA.60
TTFields-induced ‘BRCAness’ could also enhance the response
to radiotherapy. This effect has been demonstrated in a number of
preclinical research projects.55,115,116 It could, therefore, be
hypothesised that the simultaneous delivery of TTFields with
chemoradiotherapy in the clinic should maximise the DNA-
damage-response-modulating influence of TTFields and might
lead to a synergistic effect. Encouragingly, a pilot study of TTFields
concomitant with radiotherapy and TMZ in ten newly diagnosed
GBM patients demonstrated that this regimen does not increase
toxicity.117 This study is being expanded in a Phase 2 clinical trial
(NCT03869242), and a similar Phase 3 trial is currently in
registration (TRIDENT—see Table 1). Finally, future studies should
also aim to identify and characterise predictive biomarkers that
could help to identify which patients most likely benefit from
TTFields treatment.
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Table 1. Key TTFields clinical trials—completed and ongoing.
Intracranial tumours







(A) TTFields alone (120)
(B) Chemo alone (117)
OS: 6.6 m (TTFields) vs
6.0 mN/S
(A) PFS: 2.2 m (TTFields) vs 2.1 mN/S.
(B) OS at 1 year: 20% in both groups.
(C) Toxicity: 6% (TTFields) vs 16% (chemo) AEs(G3–4)
(P= 0.022). Confirmed TTFields-related AEs = 2%
(Grade 2 skin AEs).
(D) QoL: ↑ cognitive & emotional, slight ↓ physical
functioning.
• TTFields as effective (OS/PFS) as physician’s choice
chemotherapy.
• ↓ Severe AEs and overall ↑ QoL.









(A) TTFields + TMZ (466)
(B) TMZ alone (229)
PFS: 6.7 m (TTFields+
TMZ) vs 4.0 m (P < 0.2006)
(A) OS: 20.9 m (TTFields+ TMZ) vs 16m (P < 0.001).
(B) Toxicity: 48% (TTFields+ TMZ) vs 44%
AEs(G3–4)—TTFields-related= 2% (all grade 3 skin).
(C) Tolerability: sig. delay in 6-pt MMSE decline and
10-pt KPS decline.
• Randomisation after initial radiochemotherapy.
• Patients alive at 5 y post randomisation = 13% (TTFields
+ TMZ) vs 5% (P= 0.004).
• TTFields improved survival with no added toxicity or
compromise in QoL.
• Led to FDA approval for TTFields with TMZ for nGBM














OS (A) PFS (median and at 2, 6 and 12m).
(B) OS at 1 and 2 years.
(C) Radiological response (ORR, RANO).
(D) Toxicity (AEs).
(E) QoL (EORTC QLQ C30).
(F) Pathological Δ in resected rGBM post treatment.
• Study to establish the efficacy and safety of 200-kHz
TTFields in combination with RT (and TMZ) in patients
with nGBM.
• Builds on preclinical work suggesting synergy between
TTFields and RT.55,115,116
• RT delivered through the TTFields arrays to maximise























(D) Radiological response (RANO-BM &
RECIST V1.1).
(E) Neurocognitive failure.
• Study to establish the efficacy and safety of 150-kHz
TTFields in patients with brain metastases from NSCLC.
• Builds on Phase 1/2 trial of TTFields for primary lesion in
advanced NSCLC.119
• Estimated study completion: Dec 2020.
Extracranial tumours












OS: 18.2 m (A) PFS: 7.6 m
(B) Toxicity: 36% AEs(G3–4) + 3 (4%)
chemotherapy-related deaths—TTFields-
related = 5% (all grade 3 skin).
(C) Radiological response (mRECIST): 40%
partial response, 57% stable disease at first
F/U scan (6 weeks).
• Study aimed to identify a signal for the activity of
150 kHz TTFields with chemotherapy in patients
with unresectable malignant pleural
mesothelioma.
• Encouraging survival data compared with
historical OS of 12.1m.101
• Led to first FDA-approved mesothelioma











Time to local ('in-field')
progression: 28w
(A) (Systemic) PFS: 22 weeks.
(B) OS: 13.8 m (57% survival at 1 year)
(C) Radiological response: 15% partial
response, 49% stable disease.
(D) Toxicity: no TTFields-related SAEs.
• Study to establish the safety and potential efficacy
of TTFields in patients with NSCLC with advanced
disease following first-line therapy and eligible for
second line pemetrexed.
• Encouraging survival relative to historical control
for pemetrexed only121 (2.9 m historic vs 5m+
with TTFields).
• TTFields+ pemetrexed is safe and potentially











(A) TTFields + ICI or DOCE
(B) ICI or DOCE
OS (TTFields+ ICI/DOCE vs ICI/
DOCE alone)





(E) QoL (EORTC QLQ C30 questionnaire).
(F) Exploratory non-inferiority analysis of
TTFields+DOCE vs ICI.
Study to establish whether the addition of TTFields
to ICI or docetaxel with improve OS in stage IV
NSCLC following platinum doublet failure.





































































(A) TTFields + GEM
(B) TTFields + GEM & nab-P*
Arm added to reflect new SoC
established while trial was
ongoing.123
Toxicity (SAEs): TTFields+GEM= 85%
TTFields+GEM+ nab-P= 85%




(A) OS: 14.9 m (TTFields+ GEM) & median
OS not reached (>15m) (TTFields+ GEM
+ nab-P).
(B) PFS: 8.3 m (TTFields+ GEM) & 12.7m
(TTFields+GEM+ nab-P)
• Study to establish the safety and preliminary
efficacy of TTFields with chemotherapy in patients
with pancreatic ductal adenocarcinoma.
• One-year OS rates of 55% (TTFields+GEM) & 72%
(TTFields+GEM+ nab-P)—encouraging relative
to historic control 22% (GEM) & 35% (GEM+ nab-
P).123
• TTFields+GEM+ /-nab-P represents a safe,












(A) TTFields + GEM & nab-P






• Study to establish efficacy of TTFields with
standard-of-care GEM & nab-P to treat patients
with unresectable, locally advanced pancreatic
adenocarcinoma.









TTFields + PAC Toxicity: G3–4 AEs 55% patients – no




(A) OS: median not reached (>21m).
(B) PFS: 8.9 m.
(C) Response rate: 25% partial response,
46% stable disease.
• Study to establish the safety and preliminary
efficacy of TTFields (200 kHz) with PAC to treat
patients with recurrent, platinum-resistant ovarian
carcinoma.
• Heavily pre-treated patient cohort— median 4
prior chemotherapy lines and 2 lines on/after
platinum at enrolment.
• Encouraging median OS relative to previous
studies inc. 17.6 m, 11.3m and 6.2 m after first,
second and fourth relapse by Hanker et al.126















(C) Radiological response rate.
(D) QoL (EORTC QLQ C30).
• Study to establish efficacy of TTFields with
standard-of-care PAC to treat patients with
platinum-resistant ovarian cancer within 6 months
of last platinum therapy with ≤2 previous lines
following diagnosis of PROC and maximum total
of 5 prior lines of systemic therapy.











TTFields + sorafenib Overall response rate (patients with CR
or PR as per RECIST criteria)
(A) OS.
(B) PFS.
(C) In-field control rate at 1 year.
(D) Distant metastases-free survival at
1 year.
• Study to establish the safety and preliminary
efficacy of adding TTFields (150 kHz) to sorafenib
in patients with unresectable HCC.










TTFields + XELOX (+
Trastuzumab if HER-2
positive)
Overall response rate (A) OS.
(B) PFS.
(C) Disease control rate.
(D) Time to progression.
(E) Duration of response.
(F) 12-month OS rate.
(G) Toxicity (AEs).
• Study to establish the safety and preliminary
efficacy of TTFields (150 kHz) with SoC
chemotherapy as first-line treatment for patients
with unresectable, locally advanced or metastatic
gastroesophageal junction or gastric
adenocarcinoma.
• Estimated study completion: December 2022.
rGBM recurrent GBM, nGBM newly diagnosed GBM, NSCLC non-small-cell lung cancer, TTFields tumour-treating fields, TMZ temozolomide, SoC standard of care, DOCE docetaxel, GEM gemcitabine, nab-P nab-
paclitaxel, PAC paclitaxel, ICI immune checkpoint inhibitors, XELOX capecitabine (Xeloda) + oxaliplatin (Eloxatin), RT radiotherapy, SRS stereotactic radiosurgery, OS (median) overall survival, PFS (median)
progression-free survival, CR complete response, PR partial response, ORR overall response rate (proportion of patients with a PR or CR), F/U follow-up, QoL quality of life, AEs adverse events, AEs(G3–4) grade


























































As evident from the preclinical and clinical studies highlighted
in this review, TTFields has great potential, both in the short- and
long term, to improve outcomes for many patients diagnosed
with a range of cancers. Continuing to enhance our knowledge of
the molecular mechanisms that underpin TTFields-based cellular
toxicity and tumour specificity/therapeutic index will hopefully aid
further adoption of this new modality and integration into existing
and novel treatment strategies to improve outcomes for a wide
range of cancer patient cohorts.
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